Miranda, André Miguel http://orcid.org/0000-0002-0175-9938
Ashok, Archana
Chan, Robin Barry
Zhou, Bowen
Xu, Yimeng
McIntire, Laura Beth
Area-Gomez, Estela
Di Paolo, Gilbert
Duff, Karen E. http://orcid.org/0000-0002-6177-868X
Oliveira, Tiago Gil http://orcid.org/0000-0003-0509-0562
Nuriel, Tal http://orcid.org/0000-0002-5252-8048
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute on Aging (AG047797, AG061264, AG062271, AG047954, NS084328, AG048408)
U.S. Department of Health & Human Services | NIH | National Institute on Aging
BrightFocus Foundation
Alzheimer’s Association (AARG-19-619164)
Cure Alzheimer’s Fund
U.S. Department of Health & Human Services | NIH | National Institute on Aging
U.S. Department of Health & Human Services | NIH | National Institute on Aging
U.S. Department of Health & Human Services | NIH | National Institute on Aging
U.S. Department of Health & Human Services | NIH | National Institute on Aging
U.S. Department of Health & Human Services | NIH | National Institute of Neurological Disorders and Stroke (NS071836)
Article History
Received: 18 January 2022
Revised: 10 February 2022
Accepted: 25 February 2022
First Online: 29 March 2022
Competing interests
: GDP is a full-time employee and shareholder of Denali Therapeutics Inc. GDP and TGO are inventors on the patent WO2010138869A1 entitled “Modulation of phospholipase D for the treatment of neurodegenerative disorders”. KED serves on the board and KED and TGO are scientific advisors and shareholders of Ceracuity Inc.